Ray Therapeutics Receives FDA Designation for Retinitis Pigmentosa Therapy

Got story updates? Submit your updates here. ›

Ray Therapeutics, a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead candidate, RTx-015, for the treatment of retinitis pigmentosa (RP). The RMAT designation provides Ray Therapeutics with access to FDA guidance on efficient drug development and the potential for priority review as it advances RTx-015 into late-stage clinical trials.

Why it matters

Retinitis pigmentosa is a rare, inherited retinal disorder that leads to progressive vision loss and blindness. The RMAT designation for RTx-015 represents a significant milestone for Ray Therapeutics as it works to bring a potentially transformative therapy to patients with advanced vision impairment from RP.

The details

RTx-015 is an optogenetic gene therapy designed to restore visual function by reprogramming targeted retinal cells. Unlike other approaches that focus on slowing disease progression, Ray Therapeutics' technology aims to actively improve patients' visual capabilities. As RTx-015 advances, the company is prioritizing efficacy endpoints that demonstrate meaningful improvements in patients' real-world visual function and quality of life.

• Ray Therapeutics received the RMAT designation from the FDA on April 2, 2026.

What they’re saying

What’s next

As RTx-015 progresses into late-stage clinical development, Ray Therapeutics is prioritizing efficacy endpoints that demonstrate meaningful improvement in patients' visual function and quality of life.